Why Strong Evidence Still Isn’t Enough & What It Takes to Secure Access, Pricing & Reimbursement in Today’s Market
- Understanding why robust clinical and real-world evidence still fails to translate into payer approval and favorable access outcomes
- Navigating the realities of pricing, policy, and reimbursement frameworks that influence decisions beyond the strength of the data
- Aligning evidence generation with payer expectations early to avoid delays, restrictions, and lost commercial value